Evaluation, Treatment, and Natural History of Children With Cancer

This study is currently recruiting participants.
Verified April 2013 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00001686
First received: November 3, 1999
Last updated: March 14, 2014
Last verified: April 2013
  Purpose

This protocol is designed to evaluate children with cancer who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific importance or educational value.


Condition
Ewing's Sarcoma
Leukemia
Lymphoma
Neoplasm
Sarcoma

Study Type: Observational
Official Title: Treatment of Children With Cancer

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 500
Study Start Date: December 1997
Detailed Description:

Background:

Children are referred to the Pediatric Oncology Branch (POB) for possible enrollment in clinical protocols for the treatment of cancer. While some children are not eligible for a specific protocol, they may present with disease manifestations that offer the potential for important new insights into the pathogenesis or clinical behavior of their underlying disease. In addition, children who have completed participation in a clinical protocol but do not currently have therapeutic protocol alternatives may continue to provide POB with important information. Diseases of interest to the POB include, but are not limited to lymphoma, brain tumors, Ewings sarcoma, leukemia, neuroectodermal tumors, osteosarcoma, and rhabdomyosarcoma. Hence, serial clinical evaluation of such patients, including the performance of clinical, laboratory, and diagnostic studies to help elucidate longitudinally the underlying disease mechanisms, and when clinically indicated standard care therapies, will assist POB meet its overall mission.

Objectives:

To be able to follow and evaluate children with cancer or pre-cancer syndromes referred to the Pediatric Oncology Branch who present with disease manifestations that lend themselves to clinical evaluation and are of unique scientific import.

Eligibility:

Patients who are evaluated by the Pediatric Oncology Branch and are: Children with cancer (or a pre-cancer syndrome), between the age(s) of 3 months - 40 years who present with disease manifestations of special interest to Pediatric Oncology Branch investigators, because they are likely to shed led light on disease pathogenesis or the clinical behavior of the disorder. Patients between the ages of 30 and 40 years may be evaluated on this protocol if their cancer (or pre-cancer syndrome) is of specific interest to the Pediatric Oncology Branch.

Design:

The medical procedures or tests will be selected for each patient on the basis of his/her individual diagnosis (or presumed diagnosis). When clinically indicated, standard therapy will be administered and patients will be followed according to standard medical practice. Specimens may be collected for clinical care purposes only to evaluate the patient s status.

No investigational tests, drugs or therapies will be administered in this protocol.

  Eligibility

Ages Eligible for Study:   3 Months to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

Patients who are evaluated by the Pediatric Oncology Branch and are:

Children with cancer (or a precancer syndrome), between the age(s) of 3 months to 40 years.

Patients between the ages of 30 and 40 years may be evaluated on this protocol if their cancer (or precancer syndrome) is of specific interest to the Pediatric Oncology Branch.

Patients with cancer (or a precancer syndrome), who present with disease manifestations of special interest to Pediatric Oncology Branch investigators, including but not limited to, lymphoma, brain tumors, Ewings sarcoma, leukemia, neuroectodermal tumors, osteosarcoma, rhabdomysarcoma.

If indicated, availability of a parent or legal guardian to give informed consent.

Patients, and, when indicated, parent or legal guardian who are deemed sufficiently reliable to return for recommended follow-up visits.

Patients greater than or equal to 18 years of age must be able to give informed consent.

EXCLUSION CRITERIA:

Patients younger than 3 months of age.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001686

Contacts
Contact: Lauren M Long, R.N. (301) 451-9921 longl@pbmac.nci.nih.gov
Contact: Crystal L Mackall, M.D. (301) 402-5940 mackallc@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    (888) NCI-1937      
Sponsors and Collaborators
Investigators
Principal Investigator: Crystal L Mackall, M.D. National Cancer Institute (NCI)
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00001686     History of Changes
Obsolete Identifiers: NCT00445536
Other Study ID Numbers: 980037, 98-C-0037
Study First Received: November 3, 1999
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Lymphoma
Sarcoma
Leukemia
Brain Tumors
Ewing's Sarcoma
Neuroectodermal Tumors
Osteosarcoma
Rhabdomyosarcoma
Children
Neoplasm

Additional relevant MeSH terms:
Sarcoma, Ewing's
Neoplasms
Leukemia
Lymphoma
Sarcoma
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Osteosarcoma
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue

ClinicalTrials.gov processed this record on April 17, 2014